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they remain poorly understood.
Aim of work: To investigate inﬂammatory markers, markers of endothelial dysfunction, antiox-
idant vitamins and rheumatoid arthritis-related factors as non traditional risk factors for occurrence
of carotid atherosclerosis in rheumatoid arthritis patients.
Patients and methods: Thirty RA patients were included in this study. All of them were females
and their ages ranged from 23 to 62 years with a mean of 43.95 ± 7.2 years. All of them were sub-
jected to full history taking, thorough clinical examination, laboratory investigations, disease activ-
ity assessment, bone erosion assessment by Modiﬁed Larsen score and functional assessment by
health assessment questionnaire (HAQ) score. Carotid Duplex was done to measure the intima-
media thickness (IMT) and carotid plaques. The patients who proved to have carotid atherosclero-
sis by ultrasound were subjected to ultrasound examination of brachial artery ﬂow mediated dila-
tation (FMD) to conﬁrm presence of endothelial dysfunction in those patients.
Results: Ten out of 30 RA patients (33.3%) had carotid atherosclerosis in whom there was
impaired FMD denoting endothelial dysfunction. Among those patients, the risk factors thatm (E. Kassem), raghdaghone
del@hotmail.com (M. Adel),
. El-Sharnoby).
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114 E. Kassem et al.associated with occurrence of carotid atherosclerosis included higher levels of inﬂammatory mark-
ers (CRP, ESR and IL-6) and VCAM-1 (a marker of endothelial dysfunction), lower levels of anti-
oxidant vitamins A and E, and RA-related factors as longer duration of disease, increased RF titer,
increased HAQ-score, bone erosion, duration of prednisone use and prednisone cumulative dose.
Conclusion: The prevalence of carotid atherosclerosis in rheumatoid arthritis patients was
33.3%. Among those patients, a statistically signiﬁcant association was found between occurrence
of carotid atherosclerosis and inﬂammatory markers, endothelial dysfunction, antioxidant vitamins
and rheumatoid arthritis related factors.
 2011 Egyptian Society for Joint Diseases and Arthritis. Production and hosting by Elsevier B.V.
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Cardiovascular event rates are markedly increased in rheuma-
toid arthritis (RA), and RA artherogenesis remains poorly
understood [1].
The pathogenic mechanisms involved in accelerated cardio-
vascular complications in RA appear to be complex and mul-
tifactorial. Both traditional and nontraditional risk factors
potentially contribute to the increased cardiovascular risk [2].
The role of chronic inﬂammation in initiating and propa-
gating atherosclerosis is being ﬁrmly established [3]. This con-
cept of inﬂammatory-driven atherogenesis is consistent with
the plaque composition of unstable coronary lesions with an
abundance of inﬂammatory molecules and immune cells. This
appearance is similar to that of inﬂammatory synovitis in RA
[3].
Goodson et al. [4] found that raised CRP to be strongly
associated with death from CVD in patients with inﬂamma-
tory polyarthritis. In a population-based incidence cohort of
RA patients from the Mayo Clinic, ESR was both a baseline
and a time-dependent predictor of cardiovascular death [5].
Although the lipid proﬁle is not associated with atherogen-
esis, it is thought that lipid peroxidation could contribute to
the initiation and progression of atherogenesis [6]. It is known
that antioxidant vitamins like vitamin A and E protect LDL
from oxidation leading to antiatherogenic effect while low lev-
els of these antioxidants are associated with increased athero-
genic CVD in RA [7].
Endothelial dysfunction is an essential step in atherogene-
sis [8], and is recognized as an early and modulating process in
the pathophysiology of atherosclerotic cardiovascular disease
[9]. Most if not all risk factors that are related to cardiovascu-
lar disease (CVD) are also associated with endothelial dysfunc-
tion [8]. One of the methods to assess endothelial function
involves the measurement of biomarkers of endothelial activa-
tion and dysfunction as circulating vascular cell adhesion mol-
ecule (VCAM)-1, intercellular adhesion molecule (ICAM)-1,
and endothelial leukocyte adhesion molecule (ELAM)-1 (or
selectin) [10,11].
Ultrasound examination of brachial artery ﬂow-mediated
dilation (FMD) has emerged as a valuable noninvasive method
for assessing endothelial function and is developing into a
potentially useful tool in the clinical setting [12].
Measurement of intema-media thickness (IMT) of the far
wall of the common carotid artery (CCA) by high resolution
ultrasonography has been established as a clinically useful in-
dex for identifying an early-stage atherosclerosis, and common
carotid artery IMT is strongly correlated with the presence of
coronary artery disease in RA [13]. Also, Martin andGonzalez-Gay [14] stated that measurement of carotid IMT
by ultrasonography yielded a high predictive power for the
development of CV events.
The aim of this study was to investigate inﬂammatory
markers, markers of endothelial dysfunction, antioxidant vita-
mins and rheumatoid arthritis-related factors as non tradi-
tional risk factors for occurrence of carotid atherosclerosis in
rheumatoid arthritis patients.
2. Patients and methods
This study included 30 rheumatoid arthritis patients diagnosed
according to the American College of Rheumatology (ACR)
revised criteria [15]. They were collected from the outpatient
clinic of Physical Medicine & Rehabilitation Department, Tan-
ta University Hospitals. All the patients were females, their age
ranged from 23 to 62 years with a mean of 43.95 ± 7.2. The
disease duration ranged from 8 months to 20 years with a
mean of 11.8 ± 6.6 years. Ten apparently healthy females
matched for age were taken as controls for parameters of
FMD of the brachial artery.
All the patients were subjected to:
1. Full history taking.
2. Thorough clinical examination.
3. Assessment of disease activity according to Mallya and
Mac [16].
4. Functional assessment according to Stan Ford Health
Assessment Questionnaire (HAQ) score [17].
5. Plain X-ray of both hands to assess the degree of RA
progression by modiﬁed Larsen scoring of MCPJs on radio-
graphs of the hands [18].
6. Laboratory investigations.
Erythrocyte sedimentation rate (ESR) by Westergren
method.
C-reactive protein (CRP) using single radial immunodif-
fusion technique.
Rheumatoid factor (RF) in serum with latex agglutina-
tion test [19].
Vascular cell adhesion molecule (VCAM)-1 using h-s
VCAM-1 ELIZA kit from Roche Diagnostics.
Interleukin-6 (IL-6) using a sandwich enzyme-linked
immunosorbent assay (Quantikene) kits obtained from R &
D System [20].
Measurement of antioxidant vitamins A and E concen-
trations in plasma by high performance liquid chromatogra-
phy [21].
7. Assessment of carotid atherosclerosis and intima-media
wall thickness: using GE Vivid 7 Dimension echo machine
with 7.5–10 MHz linear phased array transducer with the
Figure 2 Carotid duplex scanning showing increased IMT
(IMT= 1.3 mm).
Figure 1 Carotid duplex scanning showing signiﬁcant athero-
sclerotic plaque (IMT= 2.6 mm).
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away from the side being examined. Common carotid arter-
ies were examined using posterior approach by both trans-
verse and longitudinal scans. Measurement of the intima-
media thickness (IMT) was taken at three points on each
side: common carotid artery (10 mm before the bulb), bulb
(5–10 mm cranially to the start of the bulb), and internal
carotid artery (10 mm after the ﬂow divider). The maximum
IMT (M-IMT) which is the highest IMT value among the
six segments studied were assessed [22]. According to current
sonographic criteria, IMT was considered to be normal
when M-IMT was <0.9 mm, while values >0.9 mm were
considered to be an indicative of thickened intima and M-
IMT value >1.3 mm was an indicative of atherosclerotic
plaque [23].
8. Assessment of endothelial function by FMD of the bra-
chial artery.
FMD was assessed on the brachial artery with the same
echocardiographic machine used for the assessment of carotid
IMT. The test was performed according to the International
Brachial Artery Reactive Task Force guidelines [12]. The mea-
surements were performed in the supine position on the non-
dominant arm, the brachial artery was scanned longitudinally
7 cm above the anticubital crease using 10 MHz probe. The
diameter of the brachial artery was measured on the interface
between the media and adventitia of the anterior and posterior
wall.
Hyperemia was induced by inﬂation of a pneumatic cuff at
230–250 mmHg for 4 min on the most proximal portion of the
upper arm. The arterial diameter measurement was repeated
45–60 s after sudden deﬂation of the cuff. The average of the
three measurements of basal and post hyperemia diameter
was used for the analysis. FMD was expressed as the relative
increase in brachial artery diameter during hyperemia, and de-
ﬁned as:
ðpost hyperemia diameter basal diameterÞ=basal diameter
 100
To avoid confounding by other known traditional risk fac-
tors for atherosclerosis, we used the following exclusion crite-
ria: hypertension, as deﬁned by blood pressure >150/
90 mmHg or use of antihypertensive medication; hyperlipid-
emia, as deﬁned by levels of total cholesterol >250 mg/dl,
low density lipoprotein (LDL) cholesterol >160 mg/dl, or tri-
glycerides >200 mg/dl, or the use of lipid lowering medication;
diabetes mellitus, as diagnosed according to the World Health
Organization criteria [24] or use of antidiabetic medication;
and history of ischemic heart disease or cerebrovascular event;
obesity (body mass index >30 kg/m2); or smoking. Also, pa-
tients with active infectious disease, kidney failure (creatinine
>1.4 mg/dl), neoplasm or other connective tissue diseases
were excluded.
Statistics: Analysis was done using SPSS program, version
10. Descriptive statistics were done for continuous variables by
mean and standard deviation (SD). The odds ratio (OR) was
calculated for assessing the appearance of each variable. A
lower limit of the 95% conﬁdence interval (CI) that exceeded
1.0 was taken to indicate statistical signiﬁcance in the case of
positive association and upper limit less than 1.0 in the case
of negative association. Variables were compared using stu-
dent t test.3. Results
This study included 30 RA patients. All of them were females.
Their age ranged from 23 to 62 years with a mean of
43.59 ± 7.2 years. Their disease duration ranged from 8
months to 20 years with a mean of 11.8 ± 6.6 years. The re-
sults of this study showed that 10 out of 30 RA patients
(33.3%) had M-IMT > 0.9 mm or plaques (M-IMT>
1.2 mm) (Figs. 1 and 2).
In those 10 patients with carotid lesion, the baseline diam-
eter of the brachial artery was signiﬁcantly larger as compared
to controls and the FMD of the brachial artery (endothelium
dependent response) was markedly lower in patients than in
Table 1 Brachial artery diameter and FMD in RA patients
with carotid lesion and controls.
Parameter RA patients
with carotid
lesion
Mean ± SD
Controls
Mean ± SD
p
FMD % 3.8 ± 1.1 12.4 ± 2.0 <0.001
Basal brachial
artery diameter (mm)
5.2 ± 0.3 3.3 ± 0.5 <0.05
Post-hyperemia
diameter (mm)
5.4 ± 0.2 5.9 ± 0.3 >0.05
Brachial artery diameter at baseline & post occlusive hyperemia 
(patients group)
0
1
2
3
4
5
6
1 2 3 4 5 6 7 8 9 10 11 12 13 14
No of patients
m
m
Series1
Series2
series 1=pre
        5.22+0.3
     series 2= post
          5.4+0.2
Figure 3 Basal and post-hyperemia diameter of brachial artery
in RA patients with carotid lesion with non signiﬁcant difference.
116 E. Kassem et al.controls (3.8 ± 1.1% vs 12.4 ± 2.0%) (p< 0.001) as shown in
Table 1. Also, non signiﬁcant difference was found between
the basal and post hyperemia diameter of brachial artery in pa-
tients with carotid lesion Table 1 (Fig. 3).Table 2 Association between inﬂammatory markers and markers
patients.
Variable RA patients
with carotid
lesion (n= 10)
RA patients
without carot
lesion (n= 20
Mean ± SD Mean ± SD
CRP (mg/dl) 34.8 ± 11.44 20.3 ± 6.86
ESR 1st h (mm/h) 57.2 ± 19.77 35.0 ± 11.9
IL-6 (pg/ml) 46.3 ± 32.2 40.2 ± 37.8
VCAM-1 (ng/ml) 489.2 ± 143.1 448.7 ± 145.7
Table 3 Association between antioxidant vitamins and carotid ath
Variable RA patients with carotid
lesion (n= 10)
RA pa
lesion
Mean ± SD Mean
Vitamin A
(lg/L)
540.2 ± 221.3 558.3 ±
Vitamin E
(mg/L)
10.2 ± 3.91 12.9 ±The results of this study showed that the risk factors asso-
ciated with occurrence of carotid atherosclerosis included
higher levels of inﬂammatory markers (CRP, ESR and IL-6)
and VCAM-1, a marker of endothelial dysfunction Table 2.
Among RA patients with carotid atherosclerosis, a statisti-
cally signiﬁcant association was found between occurrence of
carotid atherosclerosis and lower levels of antioxidant vitamins
A and E where their OR and 95% CI were 1.56 (1.03–0.82) and
1.09 (1.12–0.92), respectively Table 3.
As regard to RA-related factors, a statistically signiﬁcant
association was found between occurrence of carotid athero-
sclerosis and duration of disease, rheumatoid factor, HAQ
score, disease activity, Larsen score, duration of prednisone
use and prednisone cumulative dose Table 4.
4. Discussion
There is increasing strong evidence that patients with RA expe-
rience accelerated atherosclerosis. This results in an approxi-
mately two fold increase in mortality from myocardial
infarction compared to general population [5].
The results of this study showed that 10 out of the 30 RA
patients (33.3%) had carotid atherosclerotic lesions. This re-
sult was in agreement with that of [25] who found that 34%
of their RA patients had carotid plaque, that of Roman et
al. [26] where 44% of their RA patients had carotid atheroscle-
rotic plaque, that of Del Rincon et al. [27] where 30% of their
RA patients had carotid plaques. Also, Dessein et al. [1] found
that 31% of their patients had plaques and 72% had common
carotid artery IMT and no plaques. Also, Salmon and Roman
[28] found increased prevalence of carotid plaque in RA and
SLE patients compared with age- and sex-matched controls,
which remained after adjustment for traditional risk factors.
In the present study there was also deﬁnite endothelial dys-
function in all patients with atherosclerosis (who had
IMT> 0.9) expressed as impaired ﬂow mediated dilatationof endothelial dysfunction with carotid atherosclerosis in RA
id
)
Odds ratio
(OR)
95% CI p
1.90 1.08–1.90 <0.001
1.50 1.01–1.60 <0.001
1.80 1.29–1.99 <0.05
1.60 1.23–1.89 <0.001
erosclerosis in RA patients.
tients without carotid
(n= 20)
Odds ratio
(OR)
95% CI p
± SD
210.2 1.56 1.03–0.82 <0.05
3.00 1.09 1.12–0.92 <0.001
Table 4 Association between rheumatoid arthritis-related factors and carotid atherosclerosis.
Variable RA patients
with carotid
lesion (n= 10)
RA patients
without carotid
lesion (n= 20)
Odds ratio (OR) 95% CI p
Mean ± SD Mean ± SD
Duration of disease (years) 12.8 ± 6.1 11.1 ± 5.3 1.65 1.08–2.25 <0.05
RF (IU/mL) 200 ± 92.68 192 ± 89.52 2.19 1.38–3.8 <0.001
HAQ score 2.88 ± 0.2 2.51 ± 0.3 1.80 1.29–1.99 <0.05
Disease activity grade 3.1 ± 0.4 2.2 ± 0.57 1.09 1.03–1.16 <0.01
Larsen score 2.7 ± 1.4 1.6 ± 1.2 1.80 1.28–1.89 <0.05
Duration of prednisone use (months) 58.2 ± 23.2 32.7 ± 18.2 2.19 1.38–3.8 <0.001
Prednisone cumulative dose (gm) 10.16 ± 2.3 6.88 ± 2.4 1.09 1.03–1.17 <0.001
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nitric oxide (NO), and atherosclerosis is associated with im-
paired NO release due to multiple mechanisms [9]. Our results
agreed with Szentpe´tery et al. [29] and Gerli et al. [30] who
found increased ccIMT and impaired FMD in their RA pa-
tients. Also, Cox et al. [31] agreed with our results as they
proved that there were several evidences of the close relation
between endothelial dysfunction and atherosclerosis.
It is ﬁrmly established that systemic markers of inﬂamma-
tion as well as measures of endothelial function are of predic-
tive value for atherogenesis and subsequent coronary heart
disease (CHD) [32]. Also, Ozbalkan et al. [33] stated that be-
yond the traditional cardiovascular risk factors, chronic sys-
temic inﬂammation has been shown to be a crucial factor in
atherosclerosis development and progression from endothelial
dysfunction to plaque rupture and thrombosis. Del Rincon
et al. [27] found a signiﬁcant association between. laboratory
markers of systemic inﬂammation and CCA IMT and plaque
formation, both of which are non-invasive measures of
atherosclerosis.
The results of this study showed that the risk factors which
associated with occurrence of carotid atherosclerosis included
higher levels of inﬂammatory markers: CRP, ESR, IL-6 and
VCAM-1 (a marker of endothelial dysfunction). Also, these
inﬂammatory markers were signiﬁcantly higher in patients
with carotid lesion than those without lesion.
These results coincided with that of Dessein et al. [1] who
found that VCAM-1 was associated with ultrasonographically
determined CCA IMT and plaque. In a previous study con-
ducted by Wallberg-Jonsson et al., [34] in 39 RA patients,
ICAM-1 and selectin concentrations were found to be related
to ultrasonographically detected CCA and femoral artery pla-
que. Taken together, these data further support the contention
that circulating adhesion molecules are linked to CVD in RA
[1].
Katritsis et al. [35] found that CRP in particular has been
emerged as a strong predictor of carotid artery disease
(CAD) outcome and has been linked to the morphology of pla-
ques. Ridlker [36] found that CRP has shown to be both a
marker and when elevated, a risk factor for CVD independent
of other classical risk factors. In patients with RA, raised ESR
[37] and CRP [4] have predicted CVD comorbidity. In contrast
to our ﬁndings, Kumeda et al. [13] found no association
between CRP levels and CCA IMT in their RA patients. They
explained this by their use of a conventional CRP assay instead
of high-sensitivity CRP assay.Interleukin-6 (IL-6) predicted endothelial dysfunction inde-
pendent of traditional cardiovascular risk factors [38]. Also,
Dessein et al. [1] stated that IL-6 was strongly associated with
endothelial dysfunction in their RA patients. Expression of
proinﬂammatory cytokines (as IL-1, IL-6, and TNF-) and
inﬂammatory mediators inﬂuences all stages of atherosclerosis
development, from early atheroma formation to thrombus
development responsible for events such as myocardial infarc-
tion [39]. Also, Rattazzi et al. [40] concluded that circulating
IL-6 concentrations predict CVD in general population.
The results of this study showed that the risk factors asso-
ciated with occurrence of carotid atherosclerosis included low-
er levels of antioxidant vitamins A and E. Also, we found that
the plasma level of these vitamins was lower in RA patients
with carotid lesion than those without lesion with statistically
signiﬁcant difference. Karatez et al. [41] and Paredes et al. [42]
found that the plasma levels of antioxidant vitamins A and E
were lower in RA patients than controls. The increase in oxi-
dative stress due to increase in inﬂammatory cells may explain
why antioxidant vitamins decrease at the same time that the
inﬂammatory markers increase in patients with RA. These
vitamins protect LDL from oxidation, leading to an antiather-
ogenic effect due to their antioxidant capacity [42].
With regard to RA-related factors, this study showed that
there was association between occurrence of carotid athero-
sclerosis and duration of the disease, rheumatoid factor
(RF), disease activity, Larsen score, HAQ score, duration of
the prednisone use and the prednisone cumulative dose.
Roman et al. [26] found that their RA patients with plaque
tended to have longer duration of disease, higher HAQ scores
and more joint replacement. Also, Del Rincon et al. [27] found
that CCA IMT was signiﬁcantly associated with the duration
of RA, the Larsen score for MCP joints, and M-HAQ score,
independently of other confounding variables. Also, Salmon
andRoman [28] found that the presence of carotid atherosclero-
sis was associatedwith disease duration in bothRAand SLEpa-
tients. There is evidence that atherosclerosis progresses
signiﬁcantly faster in patients with enhanced bone destruction
than in those with less bone destruction [43,44]. Kumeda et al.
[13] stated that the increase in CCA IMT in RA patients with
high MCP joint Larsen score can be explained by an increase
in calcium mobilization from bone due to enhancement of bone
destruction leading to enhanced development of atherosclerosis.
Kelly and Hamilton [45] stated that there was a relationship
between RA disease activity as assessed by ESR, and probabil-
ity of death from ischemic heart disease. Turesson et al. [46]
118 E. Kassem et al.conﬁrmed that RF is related to cardiovascular disease. Also,
Dessein et al. [1] stated that RF was predictive of endothelial
dysfunction independent of traditional cardiovascular risk fac-
tors. Rheumatoid factor is produced by B cells that are highly
effective at presenting antigen to T cells [47], and T-cell activa-
tion in rheumatoid synovium is B-cell dependent [48]. In an au-
topsy report on 2 RA patients with coronary artery disease, the
coronary plaques and adventitia contained large number of B
cells, whereas in coronary artery disease it is typical for lym-
phocytic inﬁltrates which consist almost exclusively of T cells
[49]. These reports support a role for humoral mechanisms
in RA atherogenesis [1]. Goodson [50] stated that RF-positive
patients may have increased ischemic heart disease mortality
because they have increased levels of chronic inﬂammation,
and suppression of this inﬂammation may lead to improved
survival.
Kelly and Hamilton [45] stated that high-dose corticoste-
roids or long-term therapy might be expected to adversely af-
fect the traditional risk factors proﬁle by increasing blood
pressure and body mass index and worsening the lipid proﬁle.
Also, Manzi et al. [51] found a signiﬁcant association between
plaque and cumulative corticosteroid dosage as well as dura-
tion of treatment. Svenungsson et al. [52] stated that the ste-
roid treatment is often believed to be atherogenic due to
effect on plasma lipoproteins and it increases total cholesterol
LDL, especially in patients taking more than 30 mg of predni-
sone daily. Hafstrom et al. [53] concluded that low-dose pred-
nisolone did not inﬂuence endothelial function and
atherosclerosis in patients with RA as determined by B-mode
ultrasound and ﬂow-mediated dilatation (FMD) of the bra-
chial artery.
In conclusion and recommendations, atherogenesis in rheu-
matoid arthritis is a chronic inﬂammatory process in which
endothelial dysfunction, inﬂammatory markers, antioxidant
vitamins and RA-related factors play an important role. Fur-
thermore, these factors can contribute to an explanation of
the high risk of cardiovascular disease in RA patients indepen-
dent of traditional risk factors. Therefore, maximum effort
should be done to treat the underlying inﬂammatory process,
endothelial dysfunction, antioxidant vitamin deﬁciency, and
using the lowest possible dosage of corticosteroids associated
with using corticosteroid sparing therapy.
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